Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Tax Provisions (2019 - 2024)

VYNE Therapeutics (VYNE) has disclosed Tax Provisions for 5 consecutive years, with $4000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Tax Provisions changed N/A year-over-year to $4000.0, compared with a TTM value of $4000.0 through Jun 2025, changed N/A, and an annual FY2025 reading of $4000.0, changed 0.0% over the prior year.
  • Tax Provisions was $4000.0 for Q4 2024 at VYNE Therapeutics, down from $13000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $13000.0 in Q4 2022 and bottomed at -$448000.0 in Q4 2021.
  • Average Tax Provisions over 4 years is -$137800.0, with a median of $1000.0 recorded in 2020.
  • Peak annual rise in Tax Provisions hit 102.9% in 2022, while the deepest fall reached 102.9% in 2022.
  • Year by year, Tax Provisions stood at $1000.0 in 2020, then tumbled by 44900.0% to -$448000.0 in 2021, then soared by 102.9% to $13000.0 in 2022, then crashed by 69.23% to $4000.0 in 2024.
  • Business Quant data shows Tax Provisions for VYNE at $4000.0 in Q4 2024, $13000.0 in Q4 2022, and -$448000.0 in Q4 2021.